MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.
The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.
MaxiVAX is a Swiss clinical-stage biotechnology company which, having completed a first-in-man Phase I clinical study, is now planning to perform several Phase II multicenter studies in different types of cancer.
First generation cancer immunotherapies are paving the way for MaxiVAX’s personalized immunotherapy.
A novel and proprietary way to reprogram and boost the patient’s own immune system for fighting cancer.
Rue de l'Athénée 24
+41 22 552 26 13